Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition
NCT ID: NCT02743195
Last Updated: 2016-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
51 participants
INTERVENTIONAL
2016-03-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Prebiotics, such as non-digestible carbohydrates, can induce the growth or activity microorganisms that contribute to the well-being of the host. Recent studies have shown that prebiotic treatment can have beneficial effects on glucose levels, lipid metabolism, and inflammatory markers in an obese population(3). The polyphenol blend is rich in anthocyanins, which is a unique subgroup of flavonoids that have been demonstrated to impact the microbiome and have anti-inflammatory properties(4,5,6,7). This open-label study will assess the benefits of a prebiotic and polyphenol blend in healthy obese adults.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Blueberry on Gut Microbiota and Metabolic Syndrome
NCT03266055
Polyphenols, Prebiotics, the Gut Microbiome and Stress
NCT05528575
Probiotics and Gut Health
NCT01874301
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
NCT01728610
Probiotics Use and Preventing Gastrointestinal Symptoms in People Living With Overweight and Obesity.
NCT07253155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Polyphenol/prebiotic blend
Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
Polyphenol/prebiotic blend
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyphenol/prebiotic blend
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female subjects of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
Double-barrier methods
Non-hormonal intrauterine devices
Vasectomy of partner
Non-heterosexual lifestyles
3. Subjects with BMI of 29.9-39.9±1 kg/m²
4. Subjects who agree to maintain their current level of physical activity throughout the trial period
5. Subjects who agree to discontinue the use or pre- and probiotic and/or polyphenol supplements from four weeks prior to baseline and for the duration of the study
6. Subjects who agree to discontinue foods containing anthocyanins (such as blueberries, blackberries, cherries, grapes, grape juice, pomegranate, raspberries, huckleberries, strawberries, and wine) from two weeks prior to baseline and for the duration of the study
7. Healthy as determined by laboratory results and medical history
8. Subjects must agree to comply with study procedures
9. Has given voluntary, written, informed consent to participate in the study
Exclusion Criteria
2. Subjects who have used an over-the-counter or prescription laxative medication within 4 weeks prior to baseline
3. Subjects who have used prebiotic, probiotic supplements or supplemented foods within 4 weeks of enrollment
4. Use of polyphenol supplements within 4 weeks prior to baseline
5. Subjects with type I diabetes or uncontrolled type II diabetes
6. Previous history of gastrointestinal surgery (except appendectomy, hernia repair, or hemorrhoidectomy).
7. Previous history of gastrointestinal diseases (except hemorrhoids and uncomplicated diverticula), as assessed by ultrasonography, colonoscopy, or rectoscopy, or history of Clostridium difficile-associated diarrhea
8. Presence of rectal bleeding (unless due to hemorrhoids)
9. Recent weight-loss (greater than 5 kg in the past month)
10. Iron deficiency (anemia) diagnosed within 3 months of baseline
11. Subjects who were smokers within 1 year of baseline
12. Subjects with active eating disorder
13. Subjects who have used oral antibiotics within 5 weeks of baseline
14. Unstable medical condition as determined by principal investigator
15. History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years of diagnosis are acceptable.
16. Alcohol abuse or drug abuse within the past 6 months
17. Consumption of \>2 standard alcoholic drinks per day
18. Use of medicinal marijuana
19. Use of anti-inflammatory medications, more than once per week or if prescribed by a physician, 4 weeks prior to randomization and for the duration of the study
20. Participation in a clinical research trial within 30 days prior to baseline
21. Allergy or sensitivity to the test material's active or inactive ingredients
22. Allergy or sensitivity to Lactulose or Mannitol
23. Individuals who are cognitively impaired and/or who are unable to give informed consent
24. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
20 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KGK Science Inc.
INDUSTRY
Pharmanex
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tetyana Pelipyagina, MD
Role: PRINCIPAL_INVESTIGATOR
KGK Science Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KGK Synergize Inc.
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010 May 17;5(5):e10667. doi: 10.1371/journal.pone.0010667.
Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. Maturitas. 2013 May;75(1):44-50. doi: 10.1016/j.maturitas.2013.02.004. Epub 2013 Mar 11.
Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013 Feb;27(1):73-83. doi: 10.1016/j.bpg.2013.03.007.
Karlsen A, Retterstol L, Laake P, Paur I, Bohn SK, Sandvik L, Blomhoff R. Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. J Nutr. 2007 Aug;137(8):1951-4. doi: 10.1093/jn/137.8.1951.
Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M. Six-week consumption of a wild blueberry powder drink increases bifidobacteria in the human gut. J Agric Food Chem. 2011 Dec 28;59(24):12815-20. doi: 10.1021/jf2028686. Epub 2011 Nov 18.
Guglielmetti S, Fracassetti D, Taverniti V, Del Bo' C, Vendrame S, Klimis-Zacas D, Arioli S, Riso P, Porrini M. Differential modulation of human intestinal bifidobacterium populations after consumption of a wild blueberry (Vaccinium angustifolium) drink. J Agric Food Chem. 2013 Aug 28;61(34):8134-40. doi: 10.1021/jf402495k. Epub 2013 Aug 19.
Taverniti V, Fracassetti D, Del Bo' C, Lanti C, Minuzzo M, Klimis-Zacas D, Riso P, Guglielmetti S. Immunomodulatory effect of a wild blueberry anthocyanin-rich extract in human Caco-2 intestinal cells. J Agric Food Chem. 2014 Aug 20;62(33):8346-51. doi: 10.1021/jf502180j. Epub 2014 Aug 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16PMHN
Identifier Type: OTHER
Identifier Source: secondary_id
16-PHX-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.